Breaking News

OctoPlus Enters Formulation Pact

OctoPlus N.V. has signed a feasibility agreement with a top-10 biopharmaceutical company to develop a controlled release formulation for an undisclosed peptide compound.

OctoPlus N.V. has signed a feasibility agreement with a top-10 biopharmaceutical company to develop a controlled release formulation for an undisclosed peptide compound. Pending a successful evaluation, the contract may result in a full process development, manufacturing and licensing agreement. Financial terms were not disclosed.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters